Specialty Enzymes & Probiotics has announced the publication of a new clinical study demonstrating the oral health benefits for dogs of Bactase Pet PB, a proprietary enzyme blend designed for companion animal oral health formulations.
In a 30-day randomised, double-blind, placebo-controlled trial, dogs receiving twice-daily Bactase Pet PB showed significant improvements vs the placebo group.
The results found a 61-67% decrease in plaque, gingivitis and bad breath.
Why this matters
Clinical research in companion animals is rare.
This is due to a lack of dedicated funding and high costs of veterinary trials, with one scientist saying, “researchers generally research what funders fund.”
There are also significant ethical and regulatory hurdles around informed consent and animal welfare.
Instead, the pet supplement industry usually relies on in vitro evidence or adapts an ingredient with human data for use in pets.
“Conducting a double-blind, placebo-controlled trial in dogs isn’t just scientifically rigorous — it’s expensive. Most companies don’t do it,” said Reshma Rathi, Vice President of Specialty Enzymes & Probiotics.
We invested in this research because it gives formulators real confidence in what they’re bringing to market.
Bactase Pet PB is one of the only pet oral health ingredients backed by clinical trial data in dogs, offering brands reliable scientific data to stand behind.
